CohBar, Inc. Announces Scientific Presentation of CB4209/CB4211 Program for NASH at The AASLD Liver Meeting® 2017
MENLO PARK, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) and (TSXV:COB.U) (“CohBar” or the “Company”) today announced that it will present preclinical data on CB4209/CB4211, its lead drug candidate program for nonalcoholic steatohepatitis (NASH) and obesity, at The Liver Meeting® 2017, the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), being held October 20-24, 2017, in Washington, D.C. Details of the poster presentation will be announced on October 23rd during the presentation.
“The Liver Meeting® is the most prominent gathering of scientists and clinicians in the field of hepatology, and we are pleased to have the opportunity to present the promising preclinical results from our CB4209 and CB4211 lead candidates,” commented Kenneth C. Cundy, Ph.D. – Chief Scientific Officer of CohBar.
Poster #2010: “CB4209 and CB4211 Reduce the NAFLD Activity Score in the STAM Model of NASH, Reduce Triglyceride Levels, and Induce Selective Fat Mass Loss in DIO Mice.”
|Session: Poster Session IV: Steatohepatitis: Experimental|
|Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM|
|Location: Walter E. Washington Convention Center, Hall D|
About CohBar’s Lead Candidate Program
CohBar’s lead preclinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company’s founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed novel, improved analogs of the MOTS-c peptide, CB4209 and CB4211, which have demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity.
CohBar (OTCQX:CWBR) and (TSXV:COB.U) is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including NASH, obesity, type 2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.
For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include CohBar’s plans and expectations for its CB4209 and CB4211 candidate program, including statements regarding the therapeutic potential of these and other mitochondria based therapeutics. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including risks associated with initial data, including the risk that results of additional pre-clinical or clinical studies may be different from (including less favorable than) the earlier data results and may not support further clinical development. Additional risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and obtain financing necessary to continue its operations and fund its candidate programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor and Media Contact:
Jon Stern, COO
(650) 446-7888 ext. 111
Released October 4, 2017